Agilent provides xCELLigence impedance-based, label-free, real time cell analysis system and NovoCyte flow cytometers.
Accelerate to discover
Related topics
Cytek LIVE Demo : introducing the new Autofluorescence (AF) Explorer in Spectroflo 3.2.1
Sep 25, 2023
In this webinar, Cytek will be covering the new features introduced in the newest SpectroFlo 3.2.1 software release and...
Educational webinar: Introducing MARS Platform for gentle cell separation
Sep 6, 2023
Join us for a webinar where we will introduce the new MARS Platform by Applied Cells, a...
Meet us in Prague this weekend (2.-5.9) at 12th International Conference of Analytical Cytometry
Aug 29, 2023
Meet ACCELA team at 12th International Conference of Analytical Cytometry 2.-5.9.2023 in Prague, ...
Aug 17, 2023
Register for an engaging webinar led by Naz Chaudary, Ph.D., and Research Technician, Alex Wang from the...
Optimizing Gene Expression with Bioluminescence & the piggyBac System
Aug 15, 2023
Discover how bioluminescence imaging & the piggyBac gene editing system optimize & track gene expression in mouse...
Cytek webinar: High Parameter Spectral Flow Cytometry for Tumor Immunology Research
Jul 28, 2023
High Parameter Spectral Flow Cytometry for Tumor Immunology Research: This webinar will be a guide for Designing,...
Webinar: Exploring Oncology applications with the WOLF G2 Cell Sorter and N1 Single-Cell Dispenser
Jun 19, 2023
This educational webinar invites you to explore the scientific capabilities and oncology applications of the...
Webinar recording: Multimodal tissue imaging and machine learning to advance precision medicine
Jun 2, 2023
Enjoy this recorded webinar to learn how the Orion spatial biology imaging platform was used to identify prognostic...
Jul 10, 2017
Wednesday, July 12, 2017, 9 pm CEST.
Dan MacLeod Ph.D., Precision BioSciences, Inc.
At Precision BioSciences, we have developed an allogeneic method using our proprietary ARCUS gene-editing technology to generate “universal” CAR T cells from healthy donors. These cells are engineered to eliminate expression of the endogenous T cell receptor making them safe for transfer to unrelated patients. By integrating the CAR transgene at a single genomic site, we can tightly control the level of CAR expression on the cell surface. We further optimize the cells by designing new CAR T constructs that include modifications to the extracellular binding domains as well as the intracellular signaling domains. Evaluating the impact of these new modifications requires sensitive methods to assay CAR T cell function. Traditional methods for evaluating cytotoxicity cannot effectively predict in vivo activity of a CAR T product; this is because they assess short-term killing potential rather than the ability to expand, persist, and exhibit serial killing. We have used the ACEA xCELLigence instrument for both B Cell Killing Assays and Leukemic Cell Killing Assays to test multiple CAR constructs with modified ectodomains, endodomains, and other modifications, and we have found this platform sensitive enough to detect subtle yet significant differences in performance not observed in traditional killing assays. Furthermore, the sensitivity of the instrument has enabled us to evaluate CAR constructs using cell numbers that are orders of magnitude lower than other assays, greatly enhancing our throughput and capabilities.
Related technologies: Real-time, label free cell analysis
Get more info
Brand profile
Agilent provides xCELLigence impedance-based, label-free, real time cell analysis system and NovoCyte flow cytometers.
More info at:
www.aceabio.com